SYDNEY, AUSTRALIA - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (“Immutep” or “the Company”) is pleased to announce the grant of Canadian patent no. 2,685,584 entitled “Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease.”
The patent is directed to Immutep’s IMP731 antibody that was originally developed by Immutep S.A.S., Immutep’s French subsidiary. The granted claims provide broad protection for the antibody and use of the antibody for treating or preventing organ transplant rejection or treating a T-cell mediated
autoimmune disease. The patent has an expiry date of 30 April 2028, and joins corresponding patents from the same family previously granted in the United States, Europe and Japan, as announced to the market.
For further information please download PDF attached:
Download this document
